海外の治験の状況「1」での検索結果
1993件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- An open, 3-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or non-amplified estrogen receptor positive metastatic breast cancer.
- FGFR1-amplified or non-amplified estrogen receptor positive metastatic breast cancer MedDRA version: 18.1 Level: PT Classification code 10055113 Term: Breast cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 18.1 Level: LLT Classification code 10070575 Term: Estrogen receptor positive breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Belgium, Canada, France, Germany, Hungary, Italy, Spain, United Kingdom
- 2013-06-12
Authorised
- In vivo induction of heme oxygenase-1 (HO-1) in the metabolic syndrome (MetS). Influence of heme arginate (Normosang) infusion on heme oxygenase-1 activity, endothelial dysfunction, insulin resistance and adipose tissue inflammation related to the metabolic syndrome - In vivo induction of HO in MetS.
- Subjects suffer from the metabolic syndrome. Effects of study medication on insulin resistance and vascular function will be studied respectively. MedDRA version: 12.1 Level: LLT Classification code 10022489 Term: Insulin resistance MedDRA version: 12.1 Level: LLT Classification code 10052066 Term: Metabolic syndrome MedDRA version: 12.1 Level: LLT Classification code 10048554 Term: Endothelial dysfunction
- Netherlands
- 2010-06-24
Authorised
- Phase III study to compare two different chemotherapy treatments to determine whether the first line with the three drugs + bevacizumab followed by a second line with the same regimen may provide better results than treatment with two drugs + bevacizumab is the first and the second treatment line
- METASTATIC COLORECTAL CANCER;Therapeutic area: Diseases [C] - Cancer [C04]
- Italy
- 2014-11-11
Authorised
- Phase I study of TARCEVA (Erlotinib Hydrochloride, OSI-774) as a single agent in children with refractory and relapsed malignant brain tumours and in combination with irradiation in newly diagnosed brain stem glioma. - Tarceva in paediatric brain tumours
- Refractory and relapsed malignant brain tumours and newly diagnosed brain stem glioma.
- Italy, United Kingdom
- 2005-06-21
Authorised
- A randomised open-label study comparing the safety and efficacy of ritonavir boosted lopinavir and 2-3N(t)RTI backbone versus ritonavir boosted lopinavir and raltegravir in participants virologically failing first-line NNRTI/2N(t)RTI therapy: the SECOND-LINE study. - SECOND-LINE
- Chronic HIV infection MedDRA version: 12.0 Level: LLT Classification code 10008919 Term: Chronic HIV infection
- France, Germany, Ireland, United Kingdom
- 2010-02-15
Authorised
- Gene Therapy for Leukocyte Adhesion Deficiency-I (LAD-I): A Phase I Clinical Trial to Evaluate the Safety and Efficacy of the Infusion of Autologous Hematopoietic Stem Cells Transduced with a Lentiviral Vector Encoding the ITGB2 Gene
- Leukocyte Adhesion Deficiency-I (LAD-I) MedDRA version: 20.0 Level: LLT Classification code 10018137 Term: Genetic anomalies of leukocytes System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
- Spain
- 2018-08-02
Authorised
- GLP-1 analogs for Freidreich's Ataxia treatment.
- Friedreich's Ataxia;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Belgium
- 2014-09-08
Authorised
- Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer.
- Unresectable Wild-Type KRAS Metastatic Colorectal Cancer MedDRA version: 16.0 Level: LLT Classification code 10052362 Term: Metastatic colorectal cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Austria, Belgium, France, Ireland, Israel, Italy, Spain
- 2013-05-22
Authorised
- Primary prevention of type 1 diabetes in young children at high risk for type 1 diabetes using intranasal insulin
- Risk for type 1 diabetes;Therapeutic area: Diseases [C] - Immune System Diseases [C20];Risk for type 1 diabetes;Therapeutic area: Diseases [C] - Immune System Diseases [C20];Risk for type 1 diabetes;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Germany
- 2016-09-02
Authorised
- Trial aimed at evaluating the activity of the anti-ALK1 monoclonal antibody PF-03446962 in relapsed or refractory urothelial cancer (UC) failing first-line treatment.
- Relapsed or refractory urothelial cancer after failure of 1st line platinum-containing chemotherapy regimen for metastatic disease. MedDRA version: 14.1 Level: HLT Classification code 10038502 Term: Renal pelvis and ureter neoplasms malignant System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 14.1 Level: PT Classification code 10044410 Term: Transitional cell cancer of the renal pelvis and ureter recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 14.1 Level: PT Classification code 10044412 Term: Transitional cell carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 14.1 Level: PT Classification code 10066750 Term: Bladder transitional cell carcinoma recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Italy
- 2012-03-07
